US Pharma MarketingRTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investment strategy
RTW Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Last week, I sat down with Rod Wong, RTW Investments' chief investment officer, at his firm’s office overlooking NYC's Little Island, as New York Knicks' fans took over much of lower Manhattan for the team's ...
Source: Endpoints News